Objective. To create a simple model to help public health decision makers determine how to best invest limited resources in HIV treatment scale-up and prevention. Method. A linear model was developed for determining the optimal mix of investment in HIV treatment and prevention, given a fixed budget. The model incorporates estimates of secondary health benefits accruing from HIV treatment and prevention and allows for diseconomies of scale in program costs and subadditive benefits from concurrent program implementation. Data sources were published literature. The target population was individuals infected with HIV or at risk of acquiring it. Illustrative examples of interventions include preexposure prophylaxis (PrEP), community-based education (CBE), and antiretroviral therapy (ART) for men who have sex with men (MSM) in the US. Outcome measures were incremental cost, quality-adjusted life-years gained, and HIV infections averted. Results. Base case analysis indicated that it is optimal to invest in ART before PrEP and to invest in CBE before scaling up ART. Diseconomies of scale reduced the optimal investment level. Subadditivity of benefits did not affect the optimal allocation for relatively low implementation levels. The sensitivity analysis indicated that investment in ART before PrEP was optimal in all scenarios tested. Investment in ART before CBE became optimal when CBE reduced risky behavior by 4% or less. Limitations of the study are that dynamic effects are approximated with a static model. Conclusions. Our model provides a simple yet accurate means of determining optimal investment in HIV prevention and treatment. For MSM in the US, HIV control funds should be prioritized on inexpensive, effective programs like CBE, then on ART scale-up, with only minimal investment in PrEP.
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ART for HIV-infected individuals is effective at both reducing infectivity and slowing disease progression. [2] [3] [4] However, ART is expensive and requires access to medical care. 5 Hence, even in developed countries, a significant fraction of people eligible for ART do not receive it. 6, 7 Moreover, it is estimated that worldwide, for every person newly enrolled in ART in 2010, 2 new infections occurred, indicating that more prevention efforts may be needed. 6 Many HIV prevention methods are available and in use. Costs and effectiveness of the programs vary widely, from condom distribution, which may cost less than $4 per person per year but may have limited effectiveness, 8 to daily preexposure prophylaxis (PrEP) with antiretroviral drugs, which may be highly effective at preventing disease acquisition but costs more than $10,000 per person per year in the US. 9, 10 Determining the appropriate investment of a limited budget in a portfolio of HIV treatment and prevention programs is complicated by several factors. First, the HIV epidemic grows nonlinearly, so preventing one infection today could lead to many infections averted in the future. Second, treatment and prevention programs may have overlapping benefits, since the same infection cannot be prevented twice. Individuals targeted by a prevention program may also reap the indirect benefits of a treatment program. Finally, programs may exhibit economies or diseconomies of scale as they are scaled up; thus, for example, twice the investment in prevention may not yield twice the reduction in risk.
This paper develops a simple framework for determining the optimal mix of treatment and prevention programs for HIV. The goal is to maximize health benefits, either quality-adjusted life-years (QALYs) gained or HIV infections averted (an indirect measure of health benefits), subject to investment constraints. Most previous research on the cost-effectiveness of HIV control measures has focused on the costeffectiveness of treatment or prevention only, [11] [12] [13] and studies of HIV resource allocation decisions have often focused only on HIV prevention programs. [14] [15] [16] [17] [18] We consider investment in both. Prior studies that have directly compared treatment and prevention have used simulation models to assess program effectiveness, [19] [20] [21] [22] [23] [24] [25] [26] often ignoring their costs. We aim to provide a simple method of evaluating investment in treatment and prevention portfolios that is accessible to decision makers.
We simplify the resource allocation problem by approximating health benefits and costs with linear functions. Often, models that assume linearity of HIV intervention benefits do not capture epidemic effects or do so incompletely. 11, [27] [28] [29] [30] [31] Our linear estimate of health effects accounts for both primary health benefits accruing to individuals who receive prevention or treatment as well as secondary health benefits accruing to other individuals who thereby avoid infection. Other studies have approximated epidemic effects similarly 32, 33 ; we expand on this by using the estimates as inputs to the resource allocation problem. Additionally, unlike many prior resource allocation models, we allow for subadditivity of program benefits and diseconomies of scale in program costs.
In the following, we formulate and solve our model, starting with a linear formulation and then expanding it to include overlap of treatment and prevention benefits and diseconomies of scale. Next we present methods for estimating model parameters. Then we illustrate our results with the examples of ART and 2 prevention programs-PrEP and community-based education (CBE)-in men who have sex with men (MSM) in the US. We conclude with a discussion of our findings.
MODEL FORMULATION
We consider a population of adults including both HIV-infected and uninfected individuals. We assume that the status quo includes baseline levels of treatment and prevention. We consider the decision of allocating funds between scaling up treatment for eligible infected individuals and implementing incremental prevention programs for uninfected individuals over a period of T years (n -1 prevention programs are available). We define x 1 as the number of incremental people starting ART due to the scaleup and x i (i = 2, . . . , n) as the number of uninfected people reached by prevention program i over T years. We denote overall program implementation by x = (x 1 , x 2 , . . . , x n ). We assume that programs are implemented early in the time horizon and that individuals remain on ART for their lifetime and receive prevention for T years. We assume that there is a minimum acceptable level of investment in each program, x min i , and a maximum feasible level of program implementation, x max i ; thus, 0 x min i x max i (i = 1, . . . , n). Table 1 shows all model notation.
We seek to maximize net present QALYs gained, Q(x), or HIV infections averted, IA(x), from the implementation of x. These terms can be written as where 0 is no incremental investment in any programs and r is the discount factor. QALYs gained is a standardized health outcome measure, which is particularly appropriate for comparing treatment and prevention interventions, 34 but many decision makers also consider HIV infections averted, [14] [15] [16] [17] 35 so we also include that objective.
Linear Resource Allocation Problem
We define a 1 as the estimated net present number of QALYs gained per person starting ART and a i (i = 2, . . . , n) as the net present number of QALYs gained per person reached by prevention program i. We assume that these values include an estimate of the direct QALY benefit to each person reached by the programs plus an estimate of the indirect QALY benefit for persons who avoid infection as a result. We similarly define b 1 and b i as the estimated net present number of (direct and indirect) infections averted per person starting ART and per person reached by prevention program i, respectively. We describe later how these parameters can be estimated from empirical data.
Assuming no overlap in program benefits (i.e., health benefits from simultaneous program implementation equal the sum of health benefits from each program implemented alone), we can write the following objective functions:
We constrain our objective functions with a budget B such that C(x) = B, where C(x) denotes the incremental costs in the modeled population with the implementation of x. Specifically, we consider the incremental costs of treatment and prevention programs, discounted to the present at annual rate r; this accounts for the cost of the intervention itself and the savings in medical care from improved health and reduced disease transmission. Net present healthcare costs in the modeled population with the implementation of x B
Budget for HIV spending in the modeled population In the simplest form of the problem, we model costs linearly. We define C 1 as the net present cost of starting 1 additional person on ART (for life) and C i (i = 2, . . . , n) as the net present cost of reaching 1 uninfected person with prevention program i for T years.
Then total cost can be written as C x ð Þ 5 P n i 5 1
C i x i . We assume that all values for C i are positive, since a program that is costless or cost-saving would always be implemented at the maximum feasible level.
The resource allocation problem can be written as
P1 has a linear objective function and a linear budget constraint, so the optimal solution is a ''greedy'' solution (i.e., funds are allocated sequentially to programs in increasing order of their cost-to-benefit ratio until all funds are spent). 36 Specifically, for maximizing QALYs, it is optimal to invest in x min i for all programs and then invest any remaining budget as follows: invest up to x max i for the program with the smallest cost-to-benefit ratio, C i /a i (ties can be broken arbitrarily); if budget remains, repeat the process for the program with the next smallest C i /a i ; and continue until all budget is spent. This makes intuitive sense: It is optimal to invest in the programs that have the lowest ratio of costs to benefits. The results are similar when maximizing infections averted, but the comparison is between the ratios C i /b i .
We note that our problem is a resource allocation problem, not a cost-effectiveness analysis, so the cost-to-benefit ratios described here should not be confused with incremental cost-effectiveness ratios. We analyze the optimal allocation of resources among programs given a fixed budget constraint and assuming independence of intervention effects. (As we describe in the following section, we capture potential dependence between program effects with an overlap multiplier [problem P2 below].) Our analysis determines the optimal level of investment scaleup in a given program, which is different from analyzing the cost-effectiveness of 1 program incremental to another; instead, the goal is to spend a fixed budget in the most effective manner possible. The cost-to-benefit ratios C i /b i are specific to the intervention considered and do not depend on the other interventions under consideration.
Resource Allocation Problem with Overlap
Problem P1 assumes that benefits of treatment and prevention programs are purely additive. In practice, the health benefits of simultaneously implemented programs can be less than the sum of the benefits of each program if implemented alone. For example, the number of HIV infections averted from a prevention program will be less when many eligible infected individuals receive ART than when few receive ART. This is because the average infectivity of infected individuals will be lower when many individuals receive ART, thus decreasing the baseline risk faced by uninfected individuals. A number of studies of concurrent prevention and treatment programs have observed this phenomenon. 19, 25, 26, 31, 37 We denote the magnitude of overlap in QALYs gained and infections averted by the implementation of x as d q (x) and d IA (x), respectively. With this, we rewrite the resource allocation problem as
We assume that d Q (0) = 0 and d IA (0) = 0 and that these functions are increasing in x i . We describe below how these functions can be estimated. If d Q (x) and d IA (x) are concave in x, then the objective function is convex. In this case, a boundary solution is optimal, and the same rules apply for optimally investing as in P1. If d Q (x) and d IA (x) are convex in x, then the objective function is concave and the optimal solution can be determined from first-order conditions. 38 For other forms of d Q (x) and d IA (x), an analytical solution may be difficult to attain, but the problem can be solved numerically using standard methods. 38 One reasonable form for the overlap function is a Cobb-Douglas function. For example, for the case of ART and 1 prevention program, these functions are given by d Q (x) = k Q x 1 x 2 and d IA (x) = k IA x 1 x 2 , where k Q and k IA are nonnegative constants. These functions account for increasing overlap as a function of each program's implementation, captured in the term x 1 x 2 . If either x 1 or x 2 is zero, then d Q (x) and d IA (x) are zero, since overlap is only relevant when both programs are implemented. The Cobb-Douglas functions are neither convex nor concave. If these overlap functions are used, the problem can be solved numerically (see the Appendix, available online).
Resource Allocation Problem with Overlap and Increasing Marginal Costs
We further build on the resource allocation problem by considering increasing marginal costs with program scale-up (i.e., diseconomies of scale). For example, costs per person reached can increase with scale-up if individuals reached first are the easiest (cheapest) to reach or if individuals reached with scale-up are less adherent and require more investment to achieve behavior change. 37, 39 Increasing marginal costs can also serve as a proxy for diminishing returns in program effectiveness as a function of program scale-up. 40 While secondary transmission benefits can lead to substantial numbers of infections averted at low program coverage, it is likely that the growth of health benefits slows as coverage increases and benefits approach their maximum level. This has been observed, for example, for PrEP for HIV prevention in MSM. 10 As with overlap in health benefits, increasing marginal costs (or diminishing returns) may have little impact until program coverage is high.
We denote by l i (x i ) the incremental average cost per person for treatment or prevention at program coverage x i (above cost C i (x i )). We assume that l i (x i ) is a nonnegative, nondecreasing linear function, 39, 41, 42 given by l i (x i ) = a i x i -b i . Thus, the incremental cost is incurred when coverage exceeds a threshold level b i /a i . The cost function is now
where the terms C i are as defined in the previous section.
With this modification, the resource allocation problem becomes
Since the budget constraint is piecewise, there are n 3 n cases to consider and, as before, the form of d Q (x) and d IA (x) affects the analytical tractability. The problem can be solved numerically, and some specific cases can be solved analytically.
We describe in the Appendix how to find the optimal solution to the resource allocation problems P2 and P3 for the special case of ART and 1 prevention program, with overlap given by Cobb-Douglas functions.
Evaluating Cost-Effectiveness
Models of HIV resource allocation typically assume a fixed budget to be allocated to maximize health impact, [14] [15] [16] [17] [18] 35, 43 making the implicit assumption that any programs that are invested in will be incrementally cost-effective and that any minimum constraints on investment (x min i in our formulation) are appropriate. If there are no lower or upper limits on investment in any intervention, then the budget will always be spent and our framework will determine the set of investments that maximizes health benefit. In this case, there is a single dominant solution (same cost, equal or greater health benefit compared with all other possible investments) whose cost-effectiveness compared with the status quo can be readily determined.
When there are limits on investment in some or all interventions, then further analysis is needed to determine the efficiency and cost-effectiveness of alternative portfolios. In this case, one could solve the resource allocation problem separately for all possible combinations of interventions and then examine the cost-effectiveness plane to determine the incremental cost-effectiveness of various investments. We provide an example below.
PARAMETER ESTIMATION
Since the model is intended to provide decision makers with a simple method of determining the optimal allocation of resources between treatment and prevention, it is important that planners can easily estimate model inputs. We now provide a set of simple rules for estimating key model parameters, summarized in Table 2 . We define a discount factor D 5 P T t 5 1 1 1 1 r ð Þ t that we use in calculating net present values of costs and health benefits.
Estimation of Health Benefits Parameters
QALY parameters (a i ). The number of net present QALYs gained per person from ART, a 1 , can be calculated as the sum of the (net present) QALYs Table 2 Parameter Estimation Guidelines Health benefit parameters Discount factor: D 5 P T t 5 1 Net present number of infections averted per person starting ART 
Cost parameters
Discount factor: D 5 P T t 5 1 ÞÞ. An estimate for e i can be obtained from the literature.
The method of estimating s T , the average chance that a person acquires HIV in T years, depends on the characteristics of the epidemic. For a stable epidemic, such as that in the overall population of MSM in the US, s T can be calculated based on the fairly stable yearly incidence. The chance of not acquiring HIV infection in 1 year can be calculated as the number of uninfected people at the end of the year divided by the number uninfected at the start of the year. The chance of acquiring HIV within T years can then be calculated as 1 -(chance of not acquiring HIV in 1 year) T . For a rapidly growing epidemic, the calculation of s T must take into account the growth in incidence over time. In this case, we can calculate s T using incidence estimates from 2 time points in the epidemic. This could be an estimate from past years' data, a current estimate, or a projection for the future, depending on what data are available to the decision maker. The overall s T can be estimated as the average of the s T for the low and high incidence time points, with each s T calculated using the method described above.
Infections averted parameters (b i ). The net present number of infections averted per person from treatment or prevention, b 1 or b i , also depends on the characteristics of the epidemic. For a stable epidemic, to estimate b 1 we first estimate the number of new infections each year caused by treated versus untreated infected individuals. We assume this does not change over time in a stable epidemic. We estimate the number of HIV-infected individuals in the population who are currently receiving ART, based on available data. We then calculate the number of new infections caused by untreated individuals using the assumption that treated individuals' contribution to incidence is reduced by the efficacy of ART in reducing infectivity, e tx . The number of infections caused by an untreated individual in 1 year is then calculated as
and the number of infections caused by a treated individual in 1 year would be this reduced by a factor of (1 -e tx ). We multiply these numbers by the discount factor D to estimate the net present number of new infections caused in T years. Then, the difference between the number caused by an untreated individual and the number caused by a treated individual is b 1 . For a rapidly growing epidemic, the method for estimating b 1 is similar, but we use incidence estimates from 2 time points, as we do for calculating s T . We calculate the number of infections caused by an untreated individual and a treated individual, as described above, in the low-incidence year and in the high-incidence year, and then use the average of those to calculate the net present number of new infections caused in T years by each type of individual. As before, the difference is b 1 . We estimate b i for prevention program i by multiplying an individual's reduction in the chance of acquiring infection (s T e i , as described above) by the net present number of infections he would cause over T years if he became infected. In a stable epidemic, the net present number of infections caused per infected person over T years is the number of annual new infections divided by the total number of infected people at the start of the year, multiplied by the discount factor:
# new infections per year # infected at start of year 3 D:
In a rapidly growing epidemic, we calculate the number of infections caused per person per year for 2 time points in the epidemic. To be conservative, since prevention programs may exhibit diminishing returns, 10, 40, 44, 45 we use the smaller of the 2 estimates to calculate b i .
Estimation of Cost Parameters (C i )
We now provide simple rules for estimating the net present cost of starting (and maintaining) 1 additional person on ART, C 1 , and the net present cost of reaching 1 uninfected person with prevention program i for T years, C i . Each parameter is a function of the cost of either ART or prevention for 1 person as well as the savings from infections averted as a result of the person receiving ART or prevention. We define the net present savings from averting an HIV infection as s IA . This is the difference in discounted lifetime healthcare costs for an infected individual and an uninfected individual; an estimate for s IA can be obtained from the literature. For treatment, we assume that once an individual starts ART, he remains on treatment for the rest of his life. We estimate the net present lifetime costs of treatment as c 1 . This is the difference in discounted lifetime healthcare costs for an infected individual receiving ART and an infected individual who never receives treatment; this parameter can be estimated from the literature. We then calculate C 1 as C 1 ffi c 1 À s IA b 1 =D ð Þ. Similarly, we define c i as the discounted cost of prevention program i for 1 person for T years. This either can be obtained from the literature or can be calculated based on the costs of each component of the prevention program and the number of people reached by the program. In estimating C i , we additionally factor in the savings in healthcare costs from a lower chance of each individual becoming HIV infected, s T e i , and infections averted because of epidemic effects, b i . This leads to C i ffi c i À s IA s T e i 1 b i =D ð Þ ð Þ .
Estimation of Overlap Functions (d q (x) and d IA (x))
In the Appendix we outline methods for estimating k Q and k IA for the 2-program problem with Cobb-Douglas production functions. These estimates are based on program effectiveness, average incidence, time horizon T, and initial size of the susceptible population. For the case of n programs, one approach to estimating overlap is to estimate the pairwise overlap between each pair of programs, using a method such as that described in the Appendix, and then include the corresponding overlap factors whenever investment in 2 or more programs is made. We illustrate this approach in the next section.
In practice, overlap factors generally will be very small relative to the health benefits a i and b i and only noticeable when program implementation is high. Hence, it may be reasonable to ignore overlap when solving for the optimal treatment and prevention mix if implementation levels are relatively low.
For the examples below, inclusion of overlap does not change the optimal solution.
EXAMPLES: TREATMENT AND PREVENTION FOR MSM IN THE US
We illustrate our models with the 2-program examples of ART and 2 types of prevention for MSM in the US: PrEP and CBE, as well as a 3-program example that considers all 3 interventions. MSM account for 56%-61% of estimated new HIV infections in the US 46, 47 and are an important group to reach with HIV control measures. Preexposure prophylaxis with daily antiretroviral drugs (ARVs) reduced HIV acquisition by 44% among MSM in the iPrEx (Chemoprophylaxis for HIV Prevention in Men) study. 9 However, PrEP is very costly, so it is important to examine investment in PrEP compared with investment in ART. Previous studies have assessed the cost-effectiveness of PrEP compared with no PrEP for MSM in the US but have not compared it with investment in ART. 10, 27, 48 Community-based education, conversely, is a fairly low-cost intervention aimed at reducing HIV risk behaviors. One such program, the Mpowerment Project, was found to modestly reduce the prevalence and frequency of unprotected anal intercourse in young MSM. 49 A previous study found the Mpowerment Project was costeffective compared with no intervention but did not compare it with investment in ART. 50 We estimated parameter values for ART, PrEP, and CBE (Table 3) using the guidelines described above. Where necessary, we drew values from the literature or estimated them using a previously published model of the HIV epidemic in MSM in the US. 10 We examined the general adult MSM population of approximately 4.3 million men. 51, 52 We estimated 12.3% HIV prevalence in this population. Annual incidence is fairly stable at 0.8%. 47, [51] [52] [53] [54] We considered a time horizon of 20 years of program implementation and discounted costs, QALYs, and infections averted at 3% annually. 34 We considered a total budget of $10 billion, estimated as 50% of the US federal budget for domestic HIV prevention. 55 We assumed 50,000
x 1 400,000 and 10,000 x i 3,000,000; these are lower and upper limits on the number of people receiving ART and prevention program i, respectively. We assumed that a non-zero minimum investment was required for prevention program i because various factors, such as ethical and societal considerations, are involved in setting investment priorities.
PrEP and ART
When considering the 2-program problem of ART versus PrEP, for both P1 (which assumes linear costs and no intervention overlap) and P2 (which includes overlap in program effects), the optimal solution is to spend the minimum amount required on PrEP (x = 10,000 people receiving PrEP) and invest the remaining budget in ART scale-up (x 1 = 72,786 incremental people receiving ART). This is the case regardless of whether the objective is to maximize QALYs gained or infections averted. This is intuitive because the per-person benefits from ART are greater than those from PrEP, and the per-person costs are less. This allocation results in approximately 1,142,000 QALYs gained and 64,000 HIV infections averted over 20 years (Figure 1 ). We also considered the case of diminishing returns for PrEP (problem P3). We estimated that the perperson cost of PrEP increases for each person receiving PrEP once x 2 reaches 6000. The costs of ART remain linear. However, because x min 2 . 6000, the marginal cost of PrEP is increasing. The optimal investment decision remains the same as for the case of linear costs of PrEP: implement x min 2 (10,000 people receiving PrEP) and invest the remaining budget in ART. Since implementing x min 2 costs more with nonlinear costs, it is only feasible to implement up to x 1 = 72,769 incremental people receiving ART. The numbers of QALYs gained and infections averted are just slightly lower than in P1 and P2 but within the rounding of our reporting.
Community-Based Education and ART
Community-based education is a much less expensive intervention than PrEP, with a lower cost-tohealth-benefit ratio than ART. In the 2-program problem, for both P1 (linear costs and no intervention overlap) and P2 (which includes overlap in program effects), the optimal solution is to invest the maximum amount in CBE and invest the remaining budget in ART scale-up. In this example, there is budget remaining after investing in x max 2 people reached by CBE, leading to the optimal solution of x 1 = 77,754 incremental people receiving ART and x 2 = 3,000,000 people reached by CBE. This is the case regardless of whether the objective is to maximize QALYs gained or infections averted. This allocation results in approximately 1,873,000 QALYs gained and 97,000 HIV infections averted over 20 years.
For a community-based intervention, costs may be higher than in the base case for certain cities and subgroups of MSM. Hence, we considered the case of increasing marginal costs for CBE (problem P3). We estimated that the per-person cost of CBE increases once x 2 reaches 20,000. The costs of ART remain linear, but the costs of CBE are linear or quadratic, depending on the level of implementation. The QALY maximizing solution is x 1 = 84,184 incremental people receiving ART and x 2 = 72,549 people reached by CBE, with approximately 1.3 million QALYs gained. The solution that averts maximal infections is x 1 = 84,446 incremental people receiving ART and x 2 = 48,397 people reached by CBE, with approximately 74,000 HIV infections averted.
PrEP, CBE, and ART
We also considered the 3-program example of ART versus PrEP versus CBE. For P1, with the base case parameter values, the optimal solution is to spend the minimum amount required on PrEP (x 2 = 10,000 people receiving PrEP), spend the maximum possible on CBE (x 3 = 3,000,000 people receiving CBE), and invest the remaining budget in ART scale-up (x 1 = 65,877 incremental people receiving ART). This is the case regardless of whether the objective is to maximize QALYs gained or infections averted. This results in approximately 1,701,000 QALYs gained and 88,000 HIV infections averted over 20 years. To apply problem framework P2, we approximate overlap in the 3-program problem as the sum of the overlap between ART and PrEP and that between ART and CBE. The optimal solution remains unchanged, but the resulting QALYs gained and infections averted are slightly lower due the effects of overlap (approximately 1,648,000 QALYs gained and approximately 83,000 HIV infections averted over 20 years). As is intuitive, the health outcomes when all 3 programs are considered fall between those attained in the 2-program examples, but they are more similar to those attained by investment in ART and CBE, since most investment is allocated to CBE. When all 3 programs are considered, health benefits are diminished because of the constraint on minimum investment in PrEP, which is a less efficient intervention than CBE and ART; if there is no such constraint, no money is invested in PrEP and the optimal solution is the same as for the case of ART and CBE.
Comparison of Results with Dynamic Model Results
To assess the accuracy of our models, we compared the health benefits we estimated using P1 with those from a previously published dynamic model of HIV in MSM in the US. 10 Figure 2 shows QALYs gained and infections averted as estimated by each method for varying levels of investment in ART, PrEP, and CBE. The results from the 2 models are fairly similar, suggesting that the assumption of linearity in our simple model is reasonable. The optimal solution of investing maximally in ART before investing in PrEP and investing in CBE before investing in ART is consistent between the 2 models. Where there are differences between the simple and dynamic models (for ART, the linear model accurately estimates QALYs but overestimates infections averted; for CBE and PrEP, the linear model accurately estimates infections averted but overestimates QALYs), the relative scale of ART, PrEP, and CBE benefits is still consistent between the 2 models, indicating that the simple model is likely ''good enough'' for informing resource allocation decisions.
Cost-Effectiveness Analysis
The above examples have considered various combinations of the 3 interventions and with constraints on levels of investment. Figure 3 shows net present costs and QALYs for the optimal portfolio corresponding to each possible combination of interventions and assuming the upper and lower limits on investment as described above. We assumed that at most 3 million people could be reached by CBE, so when investing in just CBE, only $816 million is spent. For all other sets of interventions, the entire $10 billion budget is spent.
We can use the information in Figure 3 to ask, Given the set of interventions considered in a portfolio, is the corresponding optimal investment costeffective compared with the status quo? The least cost-effective portfolio occurs when only PrEP is considered ($113,600 per QALY gained compared with the status quo). The most cost-effective portfolio occurs when CBE is considered ($1200 per QALY gained compared with the status quo). All other portfolios have incremental cost-effectiveness ratios (ICERs, compared with the status quo) that fall between these 2 values.
We can also ask, What combinations of interventions lie on the efficient frontier, and what is their ICER compared with the next least costly alternative on the efficient frontier? For our example, the portfolio of CBE only and the portfolio of CBE and ART lie on the efficient frontier. Adding ART to a portfolio that includes CBE costs $7600 per QALY gained. For this example, then, a decision maker could conclude that it is most cost-effective to invest just in CBE but is also cost-effective to invest in ART and CBE, and that portfolios that include PrEP or do not include CBE would be dominated by other alternatives.
Sensitivity Analysis
In sensitivity analysis, we assessed how several key factors-the efficacy of the prevention program, the time horizon of program implementation, and the nature of the epidemic in the modeled populationaffect the results. Table 4 shows parameter values for the ART and PrEP scenarios examined. For simplicity, we assumed linear program costs.
In the iPrEx study, PrEP reduced HIV incidence by 73% in patients who reported or exhibited high adherence to the daily regimen. 9 With this higher efficacy (v. 44% assumed in the base case), the number of QALYs gained and infections averted per person receiving PrEP increases, and the net present per-person cost of PrEP decreases. However, ART is still a more efficient investment than PrEP and it is still optimal to spend the minimum amount on PrEP and invest the remaining budget in ART. Since the net per-person cost of PrEP is lower, there is more budget remaining after investing in x min 2 , so x 1 is higher than in the base case, with 73,316 incremental people receiving ART. Studies of PrEP among heterosexuals [56] [57] [58] [59] and injection drug users 60 have found reductions in risk of HIV acquisition ranging from 0% to 75%. For any of these efficacy levels, if achieved among MSM, our analysis shows that ART is a more efficient investment than PrEP.
The base case assumed that CBE reduces risky behavior by 8%. If CBE reduces risky behavior by only 4% or less, when the objective is to maximize infections averted, it becomes optimal to invest more than the minimum amount in ART scale-up. The optimal solution is to invest x min 2 in CBE and invest all remaining budget in ART scale-up, for 84,616 incremental people receiving ART. When maximizing QALYs gained, it only becomes optimal to invest more than the minimum amount in ART scale-up when CBE reduces risky behavior by less than 1%. In the base case we considered a 20-year time horizon for PrEP use and ART scale-up. Decision makers may prefer a shorter time horizon, since they are often concerned with short-term budgets rather than longterm expenditures. Accordingly, we examined a 5year time horizon. Again, the optimal solution is to spend the minimum amount on PrEP and invest the remaining budget in ART scale-up (x 1 = 13,433 incremental people receiving ART). However, shortening the time horizon leads to a greater decrease in the health benefits of PrEP, a 2 and b 2 , than in the benefits of ART, a 1 and b 1 (Figure 4 ). This is because treatment yields an immediate benefit, both in the QALY gain to the individual receiving treatment and in the protection conferred to others. The benefits of PrEP are more dependent on epidemic effects accumulating over time, while ART confers immediate protection to all partners of treated individuals.
The same trend can be seen with the comparison of ART and CBE. Shortening the time horizon to 5 years (v. 20 years in the base case) leads to a greater decrease in benefits from CBE than from ART. As before, the optimal solution is to invest only the minimum amount in ART scale-up and to invest all remaining funds in CBE. However, in this case there is budget remaining after investing the maximum possible amount in CBE, leading to the optimal solution of x 1 = 12,889 incremental people receiving ART and x 2 = 1,000,000 reached by CBE.
The base case considered the general MSM population in the US, which has a fairly stable HIV epidemic. A rapidly growing epidemic presents very different conditions for disease control. In sensitivity analysis, we considered an epidemic with prevalence growing from 5% to 18% over 20 years and with incidence growing from 0.7% to 2.2% during this same period. This could be similar to the epidemic in some subgroups of MSM, such as young African American MSM. 46, 47 When we solve our model for ART and PrEP in this type of epidemic, the optimal solution is again to spend the minimum amount on PrEP and invest the remaining budget in ART scale-up. With our assumed budget and minimum acceptable levels of program implementation, there is excess budget after implementing up to x max 1 (x 1 = 100,000 incremental people receiving ART), so x 2 = 28,414 people receiving PrEP. In this scenario, the ratio of PrEP health benefits, a 2 and b 2 , to ART benefits, a 1 and b 1 , is greater than in the base case. This is because prevention is relatively more important in a rapidly growing epidemic, where incidence is high and there are many potential infections to prevent. The same result is seen for CBE, but the greater number of infections averted per person in the rapidly growing epidemic leads to the program being cost-saving. In sensitivity analysis we did not consider the case of a diminishing epidemic, as there is less need and urgency for treatment and prevention investment.
As shown by these examples, the optimal balance of treatment and prevention depends heavily on the cost of the interventions. For PrEP, a very expensive preventive intervention, it is always optimal to invest only the minimum required amount in PrEP (if any) and spend the remaining budget on scaling up ART. Even with very high PrEP efficacy, the high cost of PrEP precludes it from being a better value investment than ART. Similarly, CBE is a low-cost intervention, and it is optimal to invest in CBE before ART scale-up unless CBE effectiveness is extremely low.
DISCUSSION
Treatment scale-up and prevention programs are both important in combating the HIV epidemic. Our model provides a simple yet accurate framework for determining the optimal mix of program investment.
Our analysis demonstrates that HIV budgets are often best spent on the program that offers the greatest ''bang for the buck.'' This is an intuitive finding, which is supplemented by the simple methods we outline for estimating the health benefits and costs of treatment and prevention programs. Decision makers could easily solve our model in a spreadsheet after collecting and estimating model inputs. The inputs, such as HIV incidence, prevalence, baseline ART use, and per-person cost of prevention, are less extensive than for a dynamic model and draw from data to which public health decision makers would typically have access. Additionally, for the sample analyses we carried out, the inclusion of program overlap did not change the optimal resource allocation, suggesting that good solutions can be obtained without estimating possible program overlap effects, as long as program coverage is not extremely high.
We illustrated our model with the example of ART, PrEP, and CBE in MSM in the US. We saw that it is always better to invest in ART scale-up rather than PrEP, because ART has a better ratio of health benefits to costs. Even with high PrEP efficacy or in a rapidly growing epidemic, factors that could tip the scales toward prevention, PrEP is a much less efficient use of resources than is ART scale-up. This adds interesting context to the debate on PrEP use, especially given the ethical considerations of using ARVs for uninfected individuals when many infected individuals still need treatment. 61 Community-based education is a much less costly intervention. With linear costs, it is best to invest as much as possible in such a program before investing in treatment scale-up, but if the program has increasing marginal costs, a mix of investment in ART scale-up and prevention may be optimal.
We consider the objectives of maximizing QALYs gained and HIV infections averted. For our sample analyses, the choice of objective function did not change the optimal resource allocation. In other cases, particularly when the potential portfolio includes both prevention and treatment programs, the 2 objective functions may yield different solutions. Then QALYs gained may be the most appropriate objective to consider, as it comprehensively captures benefits of both treatment and prevention. 34 Our analysis has several limitations. Our framework accounts for net present costs of treatment and prevention and their future impact on the HIV epidemic. However, decision makers may think in terms of shorter time horizons and prefer to budget accordingly. Additionally, similar to most existing HIV resource allocation models, we have framed our problem as one of allocating a given budget among a predefined set of interventions, subject to upper and lower limits on investment in each intervention. To determine the most efficient set of interventions to invest in, one must compare the costs and health benefits for each possible set of interventions. If desired, one can also use the framework to determine the diminution in health benefits (if any) arising from minimum required levels of investment in interventions. Such analysis is straightforward using our framework.
We approximate diminishing returns with nonlinear cost functions. Incorporating diminishing returns in the objective functions in addition to the cost functions could lead to a more accurate estimate of program effects. This would be a straightforward extension of the model but would affect analytical tractability. Additionally, we approximate dynamic effects with a static model. For the example problem of HIV control among MSM in the US, we showed that the resource allocation results from our static model (invest first in CBE, then ART, then PrEP) matched the results obtained using a more comprehensive dynamic model. For a very rapidly growing epidemic or when high levels of intervention coverage are considered, the static model may be a less accurate approximation of the epidemic dynamics and may overestimate health effects of interventions. The overestimation occurs because of diminishing epidemic returns as interventions are scaled up (the same infection cannot be prevented twice); such dynamic effects are not captured by the linear model. In such a case, use of a more complex dynamic model may be appropriate. We designed our model to be applicable across different settings and for many types of HIV prevention programs. Although we developed it with the intention of comparing treatment and prevention programs, it could also be used to compare only prevention programs. Just as the basic structure facilitates comparing treatment to various types of prevention programs, one could estimate inputs for various prevention programs and solve for the optimal investment accordingly. Public health officials regularly must decide how to allocate resources for HIV prevention, and our simple model could assist them in such decisions.
